Advertisement
Screener

EXAGEN INC. (XGN) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

2.3 / 5 stars · 32/70 Roast Me

EXAGEN INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

EXAGEN INC. (XGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-18.

Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2024-03-18

  • EXAGEN INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2021-03-31 was 0.00%.
  • EXAGEN INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2020-09-30 was 0.00%.
  • EXAGEN INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2020-06-30 was 0.00%.
  • EXAGEN INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2020-03-31 was 0.00%.
  • EXAGEN INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
  • EXAGEN INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
  • EXAGEN INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2021 was 0.00%.
  • EXAGEN INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2020 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2023-12-310.00%
10-K · filed 2024-03-18
2022-12-310.00%
10-K · filed 2023-03-20
2021-12-310.00%
10-K · filed 2022-03-22
2021-09-300.00%
10-Q · filed 2021-11-10
2021-06-300.00%
10-Q · filed 2021-08-09
2021-03-310.00%
10-Q · filed 2021-05-11
2020-12-310.00%
10-K · filed 2021-03-16
2020-09-300.00%
10-Q · filed 2020-11-10
0.00%
10-Q · filed 2020-11-10
2020-06-300.00%
10-Q · filed 2020-07-28
0.00%
10-Q · filed 2020-07-28
2020-03-310.00%
10-Q · filed 2020-05-11
2019-12-310.00%
10-K · filed 2020-03-25
2019-09-300.00%
10-Q · filed 2020-11-10
0.00%
10-Q · filed 2020-11-10
2019-06-300.00%
10-Q · filed 2020-07-28
0.00%
10-Q · filed 2020-07-28
2019-03-310.00%
10-Q · filed 2020-05-11
2018-12-310.00%
10-K · filed 2020-03-25
2018-09-300.00%
10-Q · filed 2019-11-12
0.00%
10-Q · filed 2019-11-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Freenome, Inc. (FRNM)United States$0.143B
BIODESIX INC (BDSX)United States$0.312B
SERA PROGNOSTICS, INC. (SERA)United States$0.062B-5.75
AMERICAN SHARED HOSPITAL SERVICES (AMS)United States$0.010B-5.64
Advanced Biomed Inc. (ADVB)$0.009B
Aclarion, Inc. (ACON)United States$0.008B
BioNexus Gene Lab Corp (BGLC)$0.004B
Fulgent Genetics, Inc. (FLGT)United States$0.593B-6.70
Lumexa Imaging Holdings, Inc. (LMRI)United States$0.951B
CASTLE BIOSCIENCES INC (CSTL)United States$1.074B-37.45